Objectlve To study the properties of goat tooth enamel electron spin resonance (ESR)dosimetry.Methods Tootll enamel samples of goats were achieved by combined mechanical and chemical treatment at the ages of l,2,3,5,and 6 years.respectively and 9 enamel samples of adult molar were obtained.These enamel samples were exposed to 137Cs γ-rays at the cumulative doses of 0,0.5,1.0,2.0,and 5.0 Gy,respectively.ESR spectra Was measured before and after exposure.Results The background signal of goat tooth samples W88 21.5,significantly lower than that of the adult molar samples(39.5).The dusimetric signal intensity of the goat enamel increased with the radiation dose in a linear manner just as that of the human molars.The average radiation sensitivity of the goat tooth samples was(34.3±1.9)/Gy,close to that of the human tooth samples.Conclusions Goat teeth can be used for retrospective radiation dose reconstruction when human teeth are unavailable,in order to previde scientific data for dose reconstruction accurately.

Objective To collect and analyze the radiation dose to patients in cardiovascular interventional procedures and the radiation dose-related indicators,in order to provide a basis for improving radiation protection of patients.MethodsThe clinical data of 26 cases of complete cardiovascular interventional procedures was collected in the municipal Grade A Class Three hospitals,including coronary angiography (CA) and percutaneous transluminal coronary angioplasty (PTCA),and the patient-received radiation doses and other related factors was studied.TLD personal dosimeter radiation field matrix method was used to measure fluorescence time,the entrance skin dose (ESD),the peak skin dose (PSD),dosearea product (DAP) and other indicators.TLD was used to measure the organ dose of the phantom under the cardiovascular interventional procedure condition.ResultsThe fluoroscopy time was (17.7 ±15.6) min during the range of 0.80-42.4 min.The average entrance skin dose (ESD) was (159 ± 138)mGy during the range of 4.40-459 mGy.The peak skin dose (PSD) was (769 ± 705) mGy during the range of 22.6 - 2.43 × 103mGy.The fluorescence time,entrance skin dose (ESD) ,peak skin dose (PSD) of the group CA + PTCA are greater than the group CA and the difference has statistical significan.The peak skin dose and the fluoroscopy time have good linear correlation (r = 0.84,P ＜ 0.01 ).Conclusion The peak skin dose the patient received in cardiovascular interventional radiological operation can be estimated through the fluoroscopy time.

OBJECTIVETo investigate the proinflammatory cytocine factors in patients with coronary artery disease by different treatments during perioperation.

METHODSTNF-alpha, IL-6, c-reactive protein (CRP) were measured in 37 patients with coronary artery disease (CAD) and 10 patients with mitral valve replacement (MVR, control group) before operation and aortic clamping or before coronary artery bypass grafting (CABG) in the patients with cardiopulmonary bypass, or before transmyocardial laser reperfusion (TMLR), when aortic declamping and 3, 6, 24 hours after operation.

RESULTSThe level of proinflammatory factors increased more significantly after operation than before operation. TNF-alpha increased more significantly in the patients with CPB than in those without CPB after operation [(4.10 +/- 0.71) pg/ml vs. (1.34 +/- 0.29) pg/ml, P < 0.05)]. IL-6 was not the different among all groups after operation. CRP was higher in the CAD patients with CPB than in the control group after operation [(12.89 +/- 0.29) pg/ml vs. (12.00 +/- 0.31) pg/ml, P < 0.05].

CONCLUSIONInflammatory response can be seen after operation in all CAD patients. In patients undergoing CABG without CPB or undergoing TMLR, the changes in flammatory response are milder than those in patients with CPB. Thus patients should undergo CABG without CPB if they are indicated.

Aged ; C-Reactive Protein ; analysis ; Cardiopulmonary Bypass ; Coronary Artery Bypass ; Coronary Disease ; immunology ; surgery ; Female ; Humans ; Interleukin-6 ; blood ; Male ; Middle Aged ; Tumor Necrosis Factor-alpha ; analysis

OBJECTIVEThis work was done to compare the validity of various imaging methods, e.g. ultrasonography (US), computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), and, especially, magnetic resonance cholangiopancreatography (MRCP) for extrahepatic bile duct carcinoma.

METHODSSixty-five such patients who were operated and confirmed by pathology were used. Sixty patients had been examined by US; 52 by CT; 20 by ERCP; 9 by PTC and 20 by MRCP. The results of these imaging methods were compared with those of operative and pathological findings.

RESULTSThe diagnostic accuracy rates of site location were US 81.7%, CT 84.6%, ERCP 75.0%, PTC 88.9% and MRCP 100%, respectively. The quality diagnostic accuracy rates were US 73.3%, CT 82.7%, ERCP 75.0%, PTC 88.9% and MRCP 95.0%, respectively.

CONCLUSIONMRCP is superior to US, CT, ERCP and PTC not only in demonstrating the position but also the nature of extrahepatic bile duct carcinoma.

Adult ; Aged ; Aged, 80 and over ; Bile Duct Neoplasms ; diagnostic imaging ; pathology ; Cholangiocarcinoma ; diagnostic imaging ; pathology ; Cholangiopancreatography, Endoscopic Retrograde ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Ultrasonography

Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied a multidimensional, high-throughput screening platform comprising patient-derived resistant liver tumor cells (PDCs), organoids (PDOs), and xenografts (PDXs) to identify drug susceptibilities for conquering lenvatinib resistance in clinically relevant settings. Expansion and passaging of PDCs and PDOs from resistant patient liver tumors retained functional fidelity to lenvatinib treatment, expediting drug repurposing screens. Pharmacological screening identified romidepsin, YM155, apitolisib, NVP-TAE684 and dasatinib as potential antitumor agents in lenvatinib-resistant PDC and PDO models. Notably, romidepsin treatment enhanced antitumor response in syngeneic mouse models by triggering immunogenic tumor cell death and blocking the EGFR signaling pathway. A combination of romidepsin and immunotherapy achieved robust and synergistic antitumor effects against lenvatinib resistance in humanized immunocompetent PDX models. Collectively, our findings suggest that patient-derived liver cancer models effectively recapitulate lenvatinib resistance observed in clinical settings and expedite drug discovery for advanced liver cancer, providing a feasible multidimensional platform for personalized medicine.